Amoéba and Koppert in final phase before the launch of AXPERA

Amoéba, a company specializing in natural microbiological solutions, continues its preparations with Koppert to commercially launch AXPERA, their biocontrol product. Discussions that began in December 2024 were constructive, leading to the obtaining of crucial authorizations.

AXPERA has received emergency approval in France to treat grapevine downy mildew. In the Netherlands, it is authorized for use on several greenhouse crops. This favorable context has reinforced Amoéba and Koppert's shared vision of the product's innovative and commercial potential.

The leaders of both companies express their enthusiasm for completing contract negotiations and beginning the commercial phase with customers. This partnership represents a significant step forward toward more sustainable agriculture.